EU antitrust regulators will rule by July 27 whether to clear Illumina’s proposed US$7.1 billion acquisition of cancer test maker Grail Inc, a European Commission filing showed on Thursday, June 17.
US life sciences company Illumina, which is also challenging the EU watchdog’s decision to review the deal even though it does not meet the EU revenue criteria, filed for EU approval on Wednesday.
The company has stated it will pursue a dual-track tactic, launching litigation against the Commission while following the EU merger process.
The EU competition enforcer can clear the deal with or without demanding concessions. It can open a four-month investigation if it has serious concerns.
It has stated the combined entity could restrict access to, or increase prices of, next-generation sequencers and reagents to the detriment of Grail rivals in genomic cancer tests.
Illumina announced the deal to buy out investors including Amazon founder Jeff Bezos last September. It spun off Grail as a separate business four years ago, but remained the company’s largest shareholder.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
